Adam Schoen

About Adam Schoen

I am an intellectual property partner and co-practice group leader of Brown Rudnick’s Global Intellectual Property Practice Group and Global Life Sciences Group. I have more than two decades of experience advising life sciences and medical device funds, companies, and academic institutions while helping my clients build, grown, invest in, buy, and sell companies of all sizes over the world. Select Representations: • Acelyrin in its $540 million IPO, one of the largest U.S. IPOs by a traditional biopharma company • Latigo Biotherapeutics in a $135 million Series A financing to develop nonopioid pain medication • Kate Therapeutics in its exclusive licensing deal with Astellas Pharma to develop and commercialize a gene therapy for a debilitating muscle disorder. I am ranked as a leading life sciences lawyer in The Legal 500 US.

Experience

1. Intellectual Property Partner

   Brown Rudnick LLP

   Sep 2009 — Present · Boston, MA, US

   Brown Rudnick is a leading international law firm that provides exceptional, client-driven service in global litigation, crisis management (restructuring, investigations and special situations), brand and reputation management, life sciences and technology. We advise on high-profile cross-border matters while providing the kind of personal attention to clients that is typically found at boutiques. Our enterprising and tenacious lawyers serve our clients around the globe from offices in key financial centers in the U.S. and the U.K, and have been recognized by, among others, Chambers USA, Legal 500, Benchmark Litigation and Law360 for excellence in their fields.

Education

• Cornell University

  BS

  1995 — 1999

• New England Law | Boston

  Doctor of Law - JD